The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00175526




Registration number
NCT00175526
Ethics application status
Date submitted
12/09/2005
Date registered
12/09/2005
Date last updated
30/05/2016

Titles & IDs
Public title
Predicting Complications in Women With Toxaemia
Scientific title
PIERS (Pre-eclampsia Integrated Estimate of RiSk) Model: Predicting Adverse Maternal Outcomes in Pre-eclampsia
Secondary ID [1] 0 0
H03-70137
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Toxemia 0 0
Condition category
Condition code
Injuries and Accidents 0 0 0 0
Poisoning
Blood 0 0 0 0
Other blood disorders
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Behaviour - preeclampsia

Behaviour: preeclampsia
This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w

Intervention code [1] 0 0
Behaviour
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To identify the maternal and fetal variables predictive of a combined adverse maternal outcome occurring within one week of hospital admission for pre-eclampsia
Timepoint [1] 0 0
Unknown at this time
Secondary outcome [1] 0 0
To identify whether these also predict the combined adverse maternal outcome at any time following admission ii to identify whether these variables can predict a combined adverse perinatal outcome both (a) within one week and (b) at any time foll
Timepoint [1] 0 0
Unknown at this time

Eligibility
Key inclusion criteria
These criteria reflect the evidence that pre-eclampsia is more than hypertension and
proteinuria, particularly at onset:

- Hypertension. sBP >140mmHg and/or dBP >90mmHg, twice, >4h apart after 20 weeks'
gestation. sBP will be included to reflect international guidelines.

- Proteinuria. 24h urinary protein >0.3g/d3, or in the absence of a 24h urine
collection: >2+ dipstick proteinuria after 20wk or a random protein:creatinine ratio
>30mg protein/mmol creatinine106-108.

- HELLP syndrome that is non-hypertensive and non-proteinuric, using Sibai's
criteria109,

- One eclamptic seizure without preceding hypertension or proteinuria ('BEST' definition
of eclampsia38).

- Women admitted with suspected 'superimposed pre-eclampsia' will also be included
(e.g., those with a history of pre-existing hypertension with new proteinuria (>2+) or
accelerated hypertension3;23;24).
Minimum age
16 Years
Maximum age
45 Years
Gender
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Occurrence of the maternal outcome (e.g., recurrent eclampsia) prior to collection of
the predictors.

- Admission to hospital in spontaneous labour (as clinicians will not attempt to stop
these labours).

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
British Columbia
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
Canada
State/province [3] 0 0
Quebec
Country [4] 0 0
New Zealand
State/province [4] 0 0
Christchurch
Country [5] 0 0
United Kingdom
State/province [5] 0 0
Leeds

Funding & Sponsors
Primary sponsor type
Other
Name
University of British Columbia
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
At present, the management of pre-eclampsia is guided by expert opinions that are not
well-based on firm evidence. What is required is a clinical tool that can accurately
determine a women's risk for adverse outcomes, and thereby reduce the risk for women while
safely prolonging pregnancies remote from term (to improve fetal outcomes). This research
project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is
specific to the condition. This severity score will be used clinically (to guide management)
and in research (in both clinical trials and basic science research), and will provide an
evidence base on which to build future practice, improving outcomes for pregnant women and
their babies. In addition, this project is part of a three part strategy to better understand
the mechanisms of disease in pre-eclampsia and to investigate a potential disease-modifying
therapy, namely, recombinant human activated protein C.
Trial website
https://clinicaltrials.gov/show/NCT00175526
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Peter von Dadelszen, MD
Address 0 0
University of British Columbia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications